Profound Medical Corporation, based in Toronto, has announced a deal to combine its TULSA-PRO system with Siemens Healthineers’ Magnetom Free.Max MR scanner to form an integrated MR-guided prostate therapy solution.

The TULSA-PRO system utilizes transurethral ultrasound ablation (TULSA) technology, which employs MR guidance to precisely target and ablate prostate tissue while preserving urinary and sexual function. The procedure is designed for patients with prostate cancer, benign prostatic hyperplasia (BPH), or those seeking treatment while under active surveillance.

The outpatient procedure requires no hospital stay, involves minimal recovery time, and accommodates a wide range of prostate sizes.
With its 0.55T field strength and 80 cm open bore design, Magnetom Free.Max offers imaging capabilities suitable for interventional procedures. Its compact design and reduced operational costs make it particularly viable for ambulatory surgical centers (ASCs) and smaller medical facilities.

The collaboration aligns with the Centers for Medicare & Medicaid Services (CMS) 2025 reimbursement updates, which recognize TULSA under Urology APC Level 7 across all treatment settings — hospital outpatient departments, ASCs, and private offices. This expanded reimbursement framework is expected to broaden access to the TULSA procedure.

“It is exciting to see these two innovative medical technology companies join forces to market a complete interventional MRI solution that will not only support the Modern Treatment Pathway for prostate disease, but also make TULSA accessible in the widest possible range of treatment settings," said Dr. Michael D. Fabrizio, professor of urology at Eastern Virginia Medical School Urology of Virginia, past president MidAtlantic Section of the American Urological Association, and co-founder of the Atlantic Clinic. "Heretofore, my large urology group partners and I have been performing RARP procedures on prostate cancer patients exclusively at a hospital, but have transitioned to our freestanding ASC (ambulatory environment) when possible."

The availability of a complete interventional MR solution will make performing the TULSA procedure in an ASC both practically and economically feasible, Fabrizio added, saying many more providers will be interested in adopting the technology.

Sales of the combined system are expected to begin in 2025, pending compatibility validations.

Back to HCB News

Rad Oncology Homepage